An update on serum amyloid A-LDL and its potential use for dyslipidemic patients receiving lipid-modulating treatment

作者：Kotani Kazuhiko^*

来源：Clinical Lipidology, 2013, 8(4): 419-423.

DOI：10.2217/CLP.13.41

• atherosclerosis
• eicosapentaenoic acid
• fibrate
• lipid disorder
• statin

LDL is modified under pathological conditions associated with inflammation and oxidative stress. Serum amyloid A-LDL (SAA-LDL) is considered a possible marker of atherosclerotic diseases. The present article reviews the clinical studies of SAA-LDL in dyslipidemic patients being treated with lipid-modulating drugs. Although limited studies are currently available, a therapeutic reduction of SAA-LDL levels could be seen following treatment of dyslipidemic patients with eicosapentaenoic acid, fibrates and statins. The SAA-LDL level may potentially be used to monitor the effectiveness of treatment in these patients, while the clinical utility of measuring the SAA-LDL level has yet to be established in large prospective clinical trials. Future studies are warranted to confirm the clinical relevance of SAA-LDL.

• 出版日期2013-8